UROV Urovant Sciences Ltd.

9.48
-0.22  -2%
Previous Close 9.7
Open 9.8
Price To Book 6.04
Market Cap 287,627,295
Shares 30,340,432
Volume 3,217
Short Ratio
Av. Daily Volume 36,141

NewsSee all news

  1. Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance

    Sumitomo Dainippon Pharma is expected to fully assume Roivant's ownership interest of Urovant Sciences (approximately 75% of outstanding Urovant shares); definitive agreement expected by the end of October

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial to be initiated 4Q 2019.
hMaxi-K
Overactive bladder (OAB)
Phase 2 top-line data due 2020.
Vibegron
Irritable bowel syndrome (IBS)
Phase 3 trial initiation announced March 27, 2019. Completion of Part 1 due 2H 2019.
Vibegron - COURAGE
Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)
Phase 3 data released March 18, 2019 - primary endpoints met.
Vibegron
Overactive bladder (OAB)
Phase 2a trial to be initiated 4Q 2019.
URO-902
Overactive bladder (OAB)

Latest News

  1. Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance

    Sumitomo Dainippon Pharma is expected to fully assume Roivant's ownership interest of Urovant Sciences (approximately 75% of outstanding Urovant shares); definitive agreement expected by the end of October